BCAL vs BRK-B
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BCAL exhibits a weak financial health profile with a Piotroski F-Score of 3/9, indicating significant concerns in profitability, leverage, and operating efficiency. Despite this, the company shows strong revenue growth (198.3% YoY) and solid earnings surprises in recent quarters, suggesting improving operational momentum. Valuation appears reasonable relative to peers with a P/E of 8.72 versus sector average of 20.71, though the lack of Altman Z-Score and incomplete balance sheet data limits confidence in financial stability. The stock trades above the Graham Number ($28.75) but below analyst target ($21.83), creating a mixed value signal.
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
Compare Another Pair
Related Comparisons
BCAL vs BRK-B: Head-to-Head Comparison
This page compares California BanCorp (BCAL) and Berkshire Hathaway Inc. (BRK-B) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.